ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Professor Thomas Tuschl Receives Max Delbrück Medal
Professor Thomas Tuschl from Rockefeller University in New York,
USA, was honoured in Berlin, Germany with the Max-Delbrück-Medal.
The German chemist developed a technique which enables
researchers to literally "turn off" specific genes. This technology is
called RNA-Interference (RNAi) and is now used in research
laboratories all over the world to silence genes in cell culture to
elucidate their function. Researchers also hope to employ RNAi-
technology to silence disease genes in order to treat eye diseases,
neurological diseases, hereditary diseases, and cancer in the future.
Professor Nikolaus Rajewsky from the Max Delbrück Center for
Molecular Medicine (MDC) Berlin-Buch, Germany held the laudatory
address.
Ribonucleid acid (RNA), the chemical relative of DNA, carries the
genetic information which enables the cell machinery to produce
proteins, the building blocks of life. However, when RNA is double-
stranded, cells act to cut it into small pieces which, in turn, stop
proteins from being made. This process occurs in plants, animals, and
humans to protect them from viral infections. It also serves to regulate
genes.
While a postdoctoral student at the Massachusetts Institute of
Technology (MIT) in Cambridge, USA, Thomas Tuschl laid the
groundwork that led to his later discovery at the Max Planck Institute
for Biophysical Chemistry in Göttingen, Germany. He could show, that
synthetic double-stranded RNA is also cut into small pieces when
inserted into cells. These small pieces, made up of 20 to 23
nucleotides, interfere with the messenger RNA and, thus, silence
genes.
In 2001, Tuschl, then working at the Max Planck Institute for
Biophysical Chemistry in Göttingen, Germany, was able to show that
RNAi also exists in human cells and that it can also specifically silence
human genes.
Thomas Tuschl was born on June 1, 1966 in Altdorf near Nuerenberg,
Germany. He studied chemistry in Regensburg and earned his PhD in
1995 at the Max-Planck Institute for Experimental Medicine in
Göttingen. During the following four years, he was a postdoctoral
student in the laboratory of Nobel laureate Phillip Sharp at the
Massachusetts Institute of Technology (MIT) in Cambridge, USA, and
also worked at the nearby Whitehead Institute for Biomedical
Research.
In 1999, he returned to Germany to become a research group leader at
the Max Planck-Institute for Biophysical Chemistry. In 2003, he was
offered a position as Associate Professor at Rockefeller University in
New York, USA, where he continues to work. A few years later he also
became Investigator of the Howard Hughes Medical Institute (HHMI).
Together with Phillip Sharp and other researchers, he founded the
biopharmaceutical company Alnylam in Cambridge, USA, in 2002,
which aims at developing novel therapeutics based on RNAi.
Thomas Tuschl has received many scientific awards in Germany and
the USA, among them the Ernst-Schering-Prize in 2005 in Berlin, and
in 2003 the Mayor's Award for Excellence in Science and Technology
in New York, the Wiley Prize in the Biomedical Sciences, and the
Newcomb Cleveland Prize of the American Association for the
Advancement of Science.
Awarded annually since 1992, the Max Delbrück Medal is presented to
outstanding scientists on the occasion of the "Berlin Lectures on
Molecular Medicine", which the MDC organizes together with other
Berlin research institutions and the Bayer Health Care, Bayer Schering
Pharma (formerly Ernst Schering Research Foundation). The first
award recipient was Professor Günter Blobel, who later received the
Nobel Prize in Medicine.
http://www.mdc-berlin.de
Profesorul Thomas Tuschl a primit Medalia Max Delbrück - Professor Thomas Tuschl Receives Max Delbrück Medal - articole medicale engleza - startsanatate